Sun Pharma Advanced Research Company Ltd (SPARC) announced that Ocuvex Therapeutics Inc. has resubmitted the Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA) to the US FDA.
The resubmission addresses facility inspection-related issues at a third-party API manufacturing site, which were highlighted in the FDA’s July 2023 CRL. The agency had not raised any concerns regarding PDP-716’s safety or efficacy.
SPARC said it will provide further updates once the FDA confirms the resubmission is complete.